RU95114742A - PHARMACEUTICAL COMPOSITION, METHOD FOR ADMINISTRATION OF HEPIRON, ORAL MEDICINAL FORM - Google Patents
PHARMACEUTICAL COMPOSITION, METHOD FOR ADMINISTRATION OF HEPIRON, ORAL MEDICINAL FORMInfo
- Publication number
- RU95114742A RU95114742A RU95114742/14A RU95114742A RU95114742A RU 95114742 A RU95114742 A RU 95114742A RU 95114742/14 A RU95114742/14 A RU 95114742/14A RU 95114742 A RU95114742 A RU 95114742A RU 95114742 A RU95114742 A RU 95114742A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- dosage form
- gepirone
- administration
- oral
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N Gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 7
- 229960000647 gepirone Drugs 0.000 claims 7
- 239000006186 oral dosage form Substances 0.000 claims 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 238000007907 direct compression Methods 0.000 claims 3
- 239000000975 dye Substances 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 229940057948 Magnesium stearate Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 1
- 229910000460 iron oxide Inorganic materials 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002035 prolonged Effects 0.000 claims 1
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US301,281 | 1994-09-06 | ||
US08/301,281 US5478572A (en) | 1994-09-06 | 1994-09-06 | Gepirone dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95114742A true RU95114742A (en) | 1997-12-10 |
RU2155044C2 RU2155044C2 (en) | 2000-08-27 |
Family
ID=23162703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95114742/14A RU2155044C2 (en) | 1994-09-06 | 1995-09-05 | Pharmaceutical composition, method of hepiron administration, oral medicinal form |
Country Status (25)
Country | Link |
---|---|
US (1) | US5478572A (en) |
EP (1) | EP0700680B1 (en) |
JP (1) | JP4540756B2 (en) |
KR (1) | KR100380806B1 (en) |
CN (1) | CN1096858C (en) |
AT (1) | ATE186462T1 (en) |
AU (1) | AU702282B2 (en) |
CA (1) | CA2157323C (en) |
CY (1) | CY2222B1 (en) |
CZ (1) | CZ286417B6 (en) |
DE (1) | DE69513254T2 (en) |
DK (1) | DK0700680T3 (en) |
ES (1) | ES2142432T3 (en) |
FI (1) | FI117319B (en) |
GR (1) | GR3032598T3 (en) |
HK (1) | HK1014666A1 (en) |
HU (1) | HU227339B1 (en) |
IL (1) | IL114984A (en) |
NO (1) | NO307814B1 (en) |
NZ (1) | NZ272855A (en) |
PL (1) | PL180691B1 (en) |
RU (1) | RU2155044C2 (en) |
SG (1) | SG30436A1 (en) |
TW (1) | TW445152B (en) |
ZA (1) | ZA957144B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068017A1 (en) * | 1996-03-25 | 2006-03-30 | Wyeth | Extended release formulation |
US20030215507A1 (en) * | 1996-03-25 | 2003-11-20 | Wyeth | Extended release formulation |
US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
CN100367965C (en) * | 1999-12-20 | 2008-02-13 | 法布瑞-克雷默制药有限公司 | Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
US6534507B1 (en) * | 1999-12-20 | 2003-03-18 | Fabre-Kramer Pharmaceuticals, Inc. | Methods for treating psychological disorders using bioactive metabolites of gepirone |
CN1479620A (en) * | 2000-12-08 | 2004-03-03 | ��˹��ŵ�� | Oral extended release formulation of gepirone |
CZ20032959A3 (en) * | 2001-05-01 | 2004-01-14 | Pfizer Products Inc. | Process for preparing a pharmaceutical composition with low dosage of a medicament and having uniform distribution and efficiency of the medicament |
PE20030527A1 (en) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT |
US20030152621A1 (en) * | 2001-11-21 | 2003-08-14 | Egberink J. G. J. | Pharmaceutical formulation of gepirone for oral administration |
TW200306866A (en) * | 2002-05-07 | 2003-12-01 | Akzo Nobel Nv | A method to improve surface properties of pharmaceutical tablets |
AU2003274110A1 (en) * | 2002-09-24 | 2004-04-19 | Akzo Nobel N.V. | Method to improve pharmaceutical tablets having a matrix of cellulose ether |
CN1819821B (en) | 2003-08-08 | 2010-10-13 | 拜奥维尔实验室国际股份有限公司 | Modified-release tablet of bupropion hydrochloride |
AR048112A1 (en) * | 2004-03-25 | 2006-03-29 | Solvay Pharm Bv | DERIVATIVES OF 1- (2H-1-BENZOPIRAN-2-ON-8-IL) -PIPERAZINE FOR PAIN TREATMENT |
AR049478A1 (en) * | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS. |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
US20060013874A1 (en) * | 2004-07-15 | 2006-01-19 | Solvay Pharmaceuticals B.V. | Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one |
PL1781292T3 (en) * | 2004-07-15 | 2011-03-31 | Abbott Healthcare Products Bv | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
JP2008519071A (en) * | 2004-11-05 | 2008-06-05 | ファーブル−クレイマー・ホールディングス・インコーポレイテッド | High-dose sustained-release formulation of gepirone |
US20060099267A1 (en) * | 2004-11-05 | 2006-05-11 | Fabre-Kramer Pharmaceuticals, Inc. | High-dosage extended-release formulation of gepirone |
EP1888080B1 (en) * | 2005-06-09 | 2010-04-14 | Euro-Celtique S.A. | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
GB1405088A (en) * | 1971-06-03 | 1975-09-03 | Mundipharma Ag | Slow release formulation |
US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4357469A (en) * | 1979-06-14 | 1982-11-02 | Forest Laboratories, Inc. | Carrier base material for prolonged release therapeutic compositions |
US4248856A (en) * | 1979-07-10 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4309406A (en) * | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4248858A (en) * | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4547358A (en) * | 1980-05-06 | 1985-10-15 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
US4690824A (en) * | 1983-07-07 | 1987-09-01 | Redi-Rowell, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4695591A (en) * | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
SE460947B (en) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | A MULTIPLE-UNIT DOS COMPOSITION OF L-DOPA |
US4771053A (en) * | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
US4782060A (en) * | 1987-07-29 | 1988-11-01 | Bristol-Myers Company | Gepirone for alleviation of panic disorders |
SE8703881D0 (en) * | 1987-10-08 | 1987-10-08 | Haessle Ab | NEW PHARMACEUTICAL PREPARATION |
SE8704097D0 (en) * | 1987-10-22 | 1987-10-22 | Astra Ab | ORAL FORMULATION OF BUSPIRONE AND SALTS THEREOF |
US5106849A (en) * | 1988-05-24 | 1992-04-21 | American Home Products Corporation | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders |
US5096908A (en) * | 1990-05-04 | 1992-03-17 | Eli Lilly And Company | Method of inhibiting gastric acid secretion |
US5189179A (en) * | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
US5124346A (en) * | 1991-04-23 | 1992-06-23 | Pfizer Inc. | Synergistic combinations in the treatment of anxiety |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5292766A (en) * | 1992-03-25 | 1994-03-08 | Eli Lilly And Company | Method for improving primary memory and/or learning |
US5378846A (en) * | 1993-06-11 | 1995-01-03 | Russian-American Institute For New Drug Development | 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives |
-
1994
- 1994-09-06 US US08/301,281 patent/US5478572A/en not_active Expired - Lifetime
-
1995
- 1995-08-16 TW TW084108546A patent/TW445152B/en active
- 1995-08-16 NO NO953212A patent/NO307814B1/en not_active IP Right Cessation
- 1995-08-17 IL IL11498495A patent/IL114984A/en not_active IP Right Cessation
- 1995-08-25 NZ NZ272855A patent/NZ272855A/en not_active IP Right Cessation
- 1995-08-25 ZA ZA957144A patent/ZA957144B/en unknown
- 1995-08-28 ES ES95113476T patent/ES2142432T3/en not_active Expired - Lifetime
- 1995-08-28 AT AT95113476T patent/ATE186462T1/en active
- 1995-08-28 DK DK95113476T patent/DK0700680T3/en active
- 1995-08-28 DE DE69513254T patent/DE69513254T2/en not_active Expired - Lifetime
- 1995-08-28 EP EP95113476A patent/EP0700680B1/en not_active Expired - Lifetime
- 1995-08-31 CA CA002157323A patent/CA2157323C/en not_active Expired - Lifetime
- 1995-09-04 KR KR1019950028717A patent/KR100380806B1/en not_active IP Right Cessation
- 1995-09-04 SG SG1995001280A patent/SG30436A1/en unknown
- 1995-09-05 CN CN95116203A patent/CN1096858C/en not_active Expired - Fee Related
- 1995-09-05 CZ CZ19952275A patent/CZ286417B6/en not_active IP Right Cessation
- 1995-09-05 FI FI954154A patent/FI117319B/en not_active IP Right Cessation
- 1995-09-05 HU HU9502599A patent/HU227339B1/en not_active IP Right Cessation
- 1995-09-05 RU RU95114742/14A patent/RU2155044C2/en not_active IP Right Cessation
- 1995-09-05 JP JP22691095A patent/JP4540756B2/en not_active Expired - Lifetime
- 1995-09-05 AU AU30438/95A patent/AU702282B2/en not_active Ceased
- 1995-09-06 PL PL95310298A patent/PL180691B1/en not_active IP Right Cessation
-
1998
- 1998-12-28 HK HK98116037A patent/HK1014666A1/en not_active IP Right Cessation
-
2000
- 2000-02-09 GR GR20000400296T patent/GR3032598T3/en unknown
-
2001
- 2001-05-04 CY CY0100008A patent/CY2222B1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95114742A (en) | PHARMACEUTICAL COMPOSITION, METHOD FOR ADMINISTRATION OF HEPIRON, ORAL MEDICINAL FORM | |
AU736243B2 (en) | Film coated tablet compositions having enhanced disintegration characteristics | |
JP2955524B2 (en) | Solid drug preparation | |
US6177102B1 (en) | Once daily analgesic tablet | |
AU719170B2 (en) | Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids | |
US6703044B1 (en) | Venlafaxine formulations | |
US8252327B2 (en) | Oral controlled release dosage form | |
US5861173A (en) | Long-lasting release nifedipine preparation | |
US5859060A (en) | Timed release tablet comprising naproxen and pseudoepherine | |
JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
ZA200309724B (en) | Oral controlled release pharmaceutical composition for one a day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
CA2392085A1 (en) | Carvedilol methanesulfonate | |
US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
WO2009118763A1 (en) | Multilayered pharmaceutical compositions and processes thereof | |
KR960010007A (en) | Gephyron Dose Type | |
US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
US6994871B2 (en) | Once a day antihistamine and decongestant formulation | |
RU2001125667A (en) | DIRECTLY PRESSED MATRIX FOR REGULATED RELEASE OF ONE-TIME DAILY DOSES OF CLARITROMYCIN | |
JPH05246845A (en) | Antipyretic analgesic agent containing ibuprofen | |
CA2386547A1 (en) | Orally disintegrating composition comprising mirtazapine | |
US5998478A (en) | Timed release tablet comprising naproxen and pseudoephedrine | |
JPS6193113A (en) | Durative preparation for oral cavity | |
CA2503380A1 (en) | Pharmaceutical compositions containing venlafaxine | |
JPH03223211A (en) | Three-layered tablet | |
US20070148241A1 (en) | Use of an intermediate for controlling the release profile of an oral formulation of a medicament |